Additionally, 2 other pillars of cardioprotective care, GLP-1 (glucagon-like peptide-1) receptor agonists and finerenone (a selective mineralocorticoid receptor antagonist) have shown various anti-inflammatory effects while proving effective in slowing CKD progression and reducing cardiovascular events, as demonstrated in the FIDELIO-DKD trial (Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease).127,128. This evidence concerns the gene NR3C2 and diabetic kidney disease.